Diovan — Class II drug recall D-0746-2026
Ongoing recall by Novartis Pharmaceuticals Corporation, reported 2026-08-19, distributed nationwide. Failed Dissolution Specifications
| Recall number | D-0746-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States |
| Recall initiated | 2026-08-04 |
| Classified | 2026-08-07 |
| Reported by FDA | 2026-08-19 |
| Distributed | Nationwide (US) |
| Reason classes | specification failure |
| NDC | 00078-0358, 00078-0358-34, 00078-0359, 00078-0359-34, 00078-0360, 00078-0360-34, 00078-0423, 00078-0423-15, 00078-1245, 00078-1245-34, 00078-1252, 00078-1252-34, 00078-1259, 00078-1259-34 |
| Lot numbers | AV5913C |
| Expiration dates | 2027-06 |
Product
Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34
Reason for recall
Failed Dissolution Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0746-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.